19 Dez 2025 | News
We are proud to share that Technophage has been awarded the ‘PME Excelência 2024’ status. This recognition highlights companies with strong performance, financial stability, and sustainable growth. For us, it reflects the hard work of our team, the trust...
30 Set 2025 | News
We are thrilled to share a major milestone in Technophage’s TP-102 clinical trial – REVERSE 2 – with the Last Patient First Visit (LPFV) now completed.This achievement reflects the dedication of our local teams and, most importantly, the commitment of every patient...
20 Jun 2025 | News
Technophage is proud to announce that it has recently been granted with the ‘COTEC Innovative Status 2025’. COTEC Portugal is the main Portuguese business association for the promotion of business innovation and technological cooperation. The COTEC Innovative Status...
31 Mar 2025 | News
Twenty years ago, Technophage started as a small startup at the Institute of Molecular Medicine, with a small adventurous team isolating bacteriophages in a lab. Today, we are an international, clinical-stage biopharma with three technological platforms, driving...
3 Jan 2025 | News
Technophage is excited to kick off the new year by sharing our latest publication in Med by Cell Press. Our Phase I/IIa study results for TP-102, an innovative bacteriophage cocktail targeting infected diabetic foot ulcers, demonstrated promising outcomes and are...
28 Nov 2024 | News
Technophage congratulates INFARMED, I.P. on the approval of phage therapy in Portugal, a groundbreaking achievement celebrated alongside the release of the “Guiding Standard on the Use of Compounded Medications for Phage Therapy in the Hospital Context – Magistral...
